President & Chief Executive Officer, Board Member

Chief Financial Officer

Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target

Dianthus initiated with bullish view at Clear Street, here's why

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

Head of Program Management

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing novel monoclonal antibodies. The Head of Program Management will establish and lead a centralized program management function, overseeing R&D and corporate programs to ensure alignment with strategic goals and timelines.

Sign up with Google

Sign in with Google